Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy
NCT ID: NCT04174456
Last Updated: 2020-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2019-12-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01150461
Treatment of Preclinical Hypertrophic Cardiomyopathy With Diltiazem
NCT00319982
Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
NCT02941705
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723
PHOspholamban RElated CArdiomyopathy STudy - Intervention
NCT01857856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors compared with other angiotensin receptor binding inhibitors. Research has been reported that statin drugs may help improve vascular endothelial function, and several researchers have suggested that these mechanisms may affect the improvement of myocardial survival. In addition, studies have shown that angiotensin receptor binding inhibitors and statins may improve left ventricular function in patients with left ventricular function. However, since the studies did not assess myocardial survival, the mechanisms could not be clearly identified.
The purpose of this study is to investigate the effect of olmesartan on myocardial survival in patients with dilated cardiomyopathy who have left ventricular dysfunction.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Olmesartan group
olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month
FDG PET
baseline and 6-month follow-up FDG PET
Valsartan group
valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month
FDG PET
baseline and 6-month follow-up FDG PET
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FDG PET
baseline and 6-month follow-up FDG PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* cardiogenic shock
* sensitive to rosuvastatin
* liver cirrhosis more than Child class B
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyungil Park
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyungil PARK
Role: STUDY_DIRECTOR
Dong-A University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine,Dong-A University College of Medicine
Busan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Jo S, Park K, Choi JH, Sohn CB, Kim J, Kwon YS, Kim SH, Park TH. A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial. J Am Heart Assoc. 2025 Jul;14(13):e041406. doi: 10.1161/JAHA.125.041406. Epub 2025 Jun 27.
Jo S, Moon H, Park K, Sohn CB, Kim J, Kwon YS, Kim SH. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022 Jan 15;23(1):36. doi: 10.1186/s13063-021-05970-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
18-215
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.